Gilead Sciences 3Q Revenues: $1.1 billion (+41%) 3Q Earnings: $398 million (net loss of $52 million in 3Q06) YTD Revenues: $3.1 billion (+47%) YTD Earnings: $1.2 billion (+155%) Comments: Sales of new HIV medication Atripla reached $241 million, after posting $68 million in 3Q06. Sales of top product Truvada increased 30% to $409 million. Overall, the HIV franchise was up 45% to $806 million, while non-HIV products Hepsera (hepatitis B) and Ambisome (severe fungal infection) contr...